Viberzi (Eluxadoline) Patent Expiration, LOE Window & CMS Spending

Viberzi (Eluxadoline) by AbbVie: FDA Orange Book core substance LOE 2029-05-27 (last listed 2033-03-14), 0 AB generics, $73.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN206940 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2029-05-27
Last Listed Patent or Exclusivity Date2033-03-14
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$73.9M
2024 Medicare Part D Spend$59.2M
2024 Medicaid Spend$14.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.